Procedural adverse events1


Procedural success rate2


Complete Closure at 12 months1

The SURPASS analysis of the NCDR-LAAO Registry™ includes the largest number of commercial WATCHMAN FLX patients to date. This data reinforces the outstanding safety of WATCHMAN FLX with 0.37% major procedural adverse event rate within 7 days or hospital discharge and 98% procedural success rate in > 16,000 real-world NVAF patients.3

How we can help you and your program


HAWKEYE is an online solution to help you facilitate LAACpatient workflow. HAWKEYE helps you understand programperformance and patient outcomes, making it easier tooptimize operational efficiencies and streamline patientcoordination.

Healthcare Solutions Team

Healthcare Solutions is a team of former hospital administrators who help LAAC programs identify opportunities to accelerate program success and development. The Calibration Program identifies and tailor solutions to optimize LAAC programs.

Connect with your peers

WATCHMAN™ Connect is a coordinator community that was designed to be a one-stop-shop. Acentral, organized, easy-to-navigate experience to learn skills and the latest best practices, tofind templates and tools, and to connect with peers in real time for responsive support.

Request access

Learn more about WATCHMAN FLX Implant

Access resources

Access WATCHMAN FLX Implant resources by visiting our WATCHMAN Download Center

Rep visit

Connect with a local representative to learn more about the WATCHMAN FLX Implant

  1. Kar S, et al. Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device: Results From the PINNACLE FLX Trial. Circulation. 2021;143:1754-1762.
  2. Late Breaking Clinical Trial at CRT 2022, Presented by Dr. Samir Kapadia
  3. Kar. S, Circulation, 2021